Patent · US Active

Use of interleukin 2 for treating Sjögren's syndrome

US11534479B2 · kind B2 · utility

0Cited by

0References

14Claims

0Family size

Assignees

ILTOO PHARMA · FR
ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS (APHP) · FR
Sorbonne Universite · FR

Inventors

David Klatzmann · Paris, FR
Roberta Lorenzon · Paris, FR
Michèle Rosenzwajg · Paris, FR
Patrice Cacoub · Dozulé, FR
Arsene Mekinian · Paris, FR

Key dates

Filing date	Feb 18, 2019
Grant date	Dec 27, 2022
Priority date	—
Expiry date	Aug 6, 2039

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to the use of interleukin-2 in treating Sjögren's syndrome in a subject, wherein IL-2 is to be administered at a low dose of less than about 3.5 MIU/day.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.